Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the October issue of Molecular Cancer Research.
...a discovery that could pave the way for more effective cancer treatments.
Scientists from J. Craig Venter Institute, Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high throughput sequencing.
Despite aggressive treatment, glioblastoma multiforme (GBM) - the most common and deadly of brain cancers - usually claims the lives of its victims within six to 12 months of diagnosis. Because GBM is so aggressive, the disease has been the target of a number of laboratory and clinical studies investigating the effectiveness of gene therapy to deliver novel therapies to the brain.
According to new research there is a suggestion that gene variants known to raise the risk of asthma, might also decrease the risk of a common type of brain cancer that progresses rapidly and is fatal.
Glioblastoma multiforme (GBM) affects three out of 100,000 people, a rate that quadruples to 13 out 100,000 among people who are 65 and older. The average five-year survival rate from the time of diagnosis for GBM is only 3.3 percent, and is lower for people 65 and older.
Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).
In the August issue of the journal Oncogene, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute describe a molecular mechanism that appears to make malignant brain tumors more vulnerable to chemotherapy after they have been treated with the dendritic cell vaccine.
Schering-Plough announced today that the European Commission has granted approval of Temodal (temozolomide) Capsules for first-line use for the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), the most common and aggressive form of primary brain cancer.
Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc. (GeneSense), has received notice from the European Patent Office of its intention to grant GeneSense's application for a patent of its novel antisense drug, GTI-2501.
Yale School of Medicine scientists have identified a virus that targets and kills glioblastoma, a deadly type of human brain tumor resistant to current medical or surgical treatment, according to a study published as the cover article in the Journal of Virology.
Researchers at Wake Forest University Baptist Medical Center have found promising new molecular targets and treatment approaches for some of the most malignant brain tumors.
The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.
The nucleus of an atom contains protons and neutrons. However, some atoms of the same chemical element can have varying numbers of neutrons, giving so-called isotopes of that element.
Schering-Plough today reported that the U.S. Food and Drug Administration (FDA) has granted approval for Temodar (temozolomide) Capsules for use in combination with radiotherapy for the treatment of adult patients with newly diagnosed glioblastoma multiforme (GBM), a form of malignant brain cancer.
A large international study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with the National Cancer Institute of Canada (NCIC) Clinical Trials Group demonstrated that the addition of a novel chemotherapy agent, Temozolomide (brand name: Temodal®) to radiation therapy increases survival in patients suffering from glioblastoma, a very aggressive form of a brain tumour.
An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.
When he's not in the operating room performing surgery, Donald M. O'Rourke, M.D., Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine is fighting brain tumors from the research laboratory bench.
A Finnish research group has been the first in the world to publish an article in which BNCT treatment has had an excellent response in a patient with head and neck cancer for whom there was no other treatment available.
Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have found that the combination of immunotherapy and chemotherapy significantly slowed tumor progression and extended survival of patients with glioblastoma multiforme (GBM).